EBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation

Similar documents
4nd Patient and Family Day

Haematopoietic stem cell transplantation (SCT)

Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. December Reference : NHSCB/B4/a/1

Comparing outcome between Belgian haematopoietic stem cell transplant centres

The Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014

Hematopoetic Stem Cell Therapies in TURKIYE

Quality and Safety of HSCT in Autoimmune Diseases

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

EPAG UPDATE. Lenja Wiehe. European Patient Advocacy Groups Manager, EURORDIS

PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey

WHO- Global perspective of hematopoieitic stem cell transplantation

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

Med A form: discussion forum

Transplants and T Cells: New Solutions for Old Problems?

A Summary of Childhood Cancer Statistics in Australia,

in cooperation with the World Health Organization Hanoi, Vietnam

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

LEGISLATIVE FRAMEWORKS AND ETHICS OF DONATION. Jeff Szer, Royal Melbourne Hospital, Australia

What are stem cells? A stem cell can differentiate into any one of 220 different specialised cells in the body STEM CELLS

Lynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines

Accreditation of BMT units & EU Regulations

MUD SCT for Paediatric AML?

What s a Transplant? What s not?

International Meeting dedicated to the memory of Raisa Gorbacheva. HEMOPOIETIC STEM CELLS TRANSPLANTATION Saint-Petersburg, September 21-22, 2007

An Overview of Blood and Marrow Transplantation

Trends in Hematopoietic Stem Cell Transplant Activity in Lebanon ( )

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris

Graft Versus Tumour Effect

Paola Di Ciaccio Vanja Nikolac

Le infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy

Update on progress of WBMT (Worldwide Network for Blood and Marrow Transplantation)

An Introduction to Bone Marrow Transplant

Blood and Marrow Transplantation: State-of-the-Art

3 rd EBMT International Transplant Course

Therapeutic Apheresis Services Annual Review 2016/17

SCI Annual Report (2017) Editorial Office

NATIONAL MARROW DONOR PROGRAM. Creating Connections. Saving Lives. Fran Rabe

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

HAEMATOPOIETIC STEM CELL TRANSPLANTATION

Welcome and introducing ESHRE

Transfusion Errors in Transplant Recipients. Paula Bolton-Maggs Alison Watt Debbi Poles Serious Hazards of Transfusion

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009

Late effects, health status and quality of life after hemopoietic stem cell

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints

THE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore

Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focusing on Immune modulatory drugs

EBV in HSCT 2015 update of ECIL guidelines

Michael Grimley 1, Vinod Prasad 2, Joanne Kurtzberg 2, Roy Chemaly 3, Thomas Brundage 4, Chad Wilson 4, Herve Mommeja-Marin 4

HSCT - Minimum Essential Data - A FOLLOW UP REPORT - ANNUAL

Reduced-intensity Conditioning Transplantation

Which is the best treatment for relapsed APL?

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant

Increase the level of science across the organization with a view to advancing clinical practice;

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda

children ISSN

Name of the Presentation

Transparency, Equity, Ethics: access to care. quality of life. Improving. and patients. An Agency of the French Ministry of Health

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focusing on Immune modulatory drugs

Samples Available for Recipient and Donor

Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Dr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK

Annual Conference of the Canadian Blood and Marrow Transplant Group. June 11 to 14, 2014 The Westin Nova Scotian 1181 Hollis Street Halifax, NS

CLINICAL MICROBIOLOGY Haematopoietic Stem Cell Transplant & National Transplant Coordination

Stem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT

PROSPERO International prospective register of systematic reviews

National Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England:

Severe Chronic Neutropenia

FORUM FOR AEROSPACE NDT BOARDS

Workshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan

Recommended Timing for Transplant Consultation

The Immunobiology Working Party

Stem Cells And The Future of Regenerative Medicine. Dipnarine Maharaj, M. D., FACP

Haematological malignancies in England Cancers Diagnosed Haematological malignancies in England Cancers Diagnosed

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT

Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017

EBMT Complications and Quality of Life Working Party Educational Course

How to prevent Infections in Patients undergoing allo-hsct?

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

Causes of Death. J. Douglas Rizzo, MD MS February, New11_1.ppt

Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -

Regence. Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT REMINDER

Late complications after hematopoietic stem cell transplant in adult patients

The European Reference Network in Rare Hematological Diseases

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012

Need considerable resources material and human.

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

Does NK cell alloreactivity prevent relapse? Yes!!! Andrea Velardi Bone Marrow Transplant Program University of Perugia

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

Stem cell transplantation. Dr Mohammed Karodia NHLS & UP

THE LEUKEMIAS. Etiology:

Late effects after HSCT

Transcription:

EBMT EBMT Organisation and Activities J Apperley 13th. ESH-EBMT Training Course Targu Mures May 24 26, 2010 History Organisation Studies Activity Philosophy EBMT Website www.ebmt.org EBMT Society European Group for Blood and Marrow Transplantation Established in 1974 and registered in Maastricht Non-profit organisation that promotes excellence in haemopoietic cell transplantation including basic and clinical research, education, standardisation, quality control and accreditation of transplant procedures

EBMT Activity survey on HSCT 1973-2007 Allogeneic HSCT, autologous HSCT, Teams Membership Overview H S C T // Structure of EBMT Quality Manager EBMT Board Executive committee Working Parties Registries Patients and Families Nurses Group Committees JACIE Accreditation Programme Status: Acute Leukaemia Aplastic Anaemia Autoimmune Diseases National Activity Survey EBMT Working Parties Board Education Total Centers registered:206 Chronic Leukaemias Immunobiology Inborn Errors Infectious Diseases Late Effects Lymphoma Paediatric Diseases Solid Tumours Austria Czech Rep France Germany Italy -Allo Italy - Auto The Netherlands Central Registry Data Office, Paris Registry Support, London Inborn Errors Cord Blood Research committee Editorial Board Nuclear Accident Quality Assessment of HSC Grafts Developmental Prospective Clinical Trials Statistical Outreach Total inspections: 171 Facilities accredited: 139 Countries:16 Switzerland Turkey UK - BMT UK - paediatric 3563 members 527 centers 57 countries Cord Blood http://www.jacie.org/ close collaboration with FACT

EBMT Committees EBMT Educational Courses 2009 Cord Blood Education Nuclear Accident response Outreach Prospective Clinical Trials Quality assessment of autologous grafts Developmental Statistical Guidelines Regulations Visions Training Courses Handbook Dates Event Venue 25 28 May 2009 The 13th EBMT-ESH Training Course: Blood and Marrow Transplantation Latimer, UK 4-6 June 2009 2nd Training Course on Bone and Marrow Transplant in Children Genoa, Italy 17 20 Sept 2009 Joint EBMT Paediatric Working Party - Raisa Gorbacheva Third Memorial Meeting on Haematopoietic Stem Cell Transplantation Saint Petersburg, Russia 23 25 Sept 2009 EBMT Inborn Errors Working Party Meeting Cambridge, UK 16 17 Oct 2009 EBMT Acute Leukaemia Working Party Meeting and Symposium Barcelona, Spain 16 17 Oct 2009 EBMT Paediatric Diseases Working Party Meeting Barcelona, Spain 22 23 Oct 2009 5th EBMT Lymphoma Working Party Educational Course Haematopoietic Stem Cell Transplantation and Lymphoma Bristol, UK 29 31 Oct 2009 12th EBMT Infectious Diseases Working Party Training Course Rome, Italy 19 20 Nov 2009 Haematopoietic Stem Cell Transplantation (HSCT) for Severe Autoimmune Diseases Meeting Florence, Italy 27 29 Nov 2009 EBMT Immunobiology Working Party Meeting Perugia, Italy Data Management Group Network of transplant data managers and statisticians EBMT Central Registry Office, London EBMT Data Office, Paris PROMISE Data Capture System, Leiden EBMT Transplant Activity Survey Office, Basel Retrospective data analysis Med A Med B Med C Transplant Activty survey Outcome analysis Quality control EBMT ACTIVITY SURVEY Current status Indication Donor type Stem Cell Source Comparison Within region Between regions Population Economics Analysis Absolute numbers By population Trends Quality control instrument Policy tool Numbers

EBMT Activity survey on HSCT in 2008: patient and transplant numbers EBMT Activity survey on HSCT in 2008: main indications Indication Allogeneic HSCT Autologous HSCT Total Indication Allogeneic 1st Tx. Autologous 1 st Tx. Total 1st transplants 10782 16028 26810 Leukaemias* Lymphoproliferative 7632 1699 978 13428 8610 15127 Retransplants Additional transplants 861 102 890 1630 1751 1732 disorders Bone marrow failures Solid tumours Non-malignant disorders 615 62 699 2 1424 172 617 1486 869 TOTAL 11745 18548 30293 Others 75 26 101 Teams: 615 Countries: 42 2008: final data Total * includes CLL 10782 16028 26810 2008: final data EBMT risk score: Age, disease stage, donor type, 7me interval, gender combina7on Impact of JACIE accreditation status 1 0,8 0,6 0,4 0,2 0 1 0 1 2 3 4 5 6-7 AML ALL CML AA MDS MM NHL 0,8 0,6 0,4 0,2 0 AML ALL CML AA MDS MM NHL 0 1 2 3 4 Cancer 5 6-7 2009;115: 4715-4726 The European The European Group Group for Blood for Blood and Marrow and Marrow Transplantation

Scientific Activities of EBMT Networking WBMT Federation 46 Publications in peer-review journals 150 Retrospective Analyses underway 8 Prospective Clinical Trials underway 350,888 Transplants in the EBMT Registry 30,293 HSCTs submitted to the Activity Survey in 2009 3612 EBMT Members across 57 Countries